Rong Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rong Yan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Kesheng Dai
Cyrus Tang Medical Institute, Jiangsu Institute of Hematology, NHC Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematological Diseases, Soochow Medical College, Soochow University, Suzhou 215123, China
3 shared publications Chenglin Sun
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
2 shared publicationsKangxi Zhou
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
2 shared publicationsQiuxia Huang
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
2 shared publicationsYue Xia
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, NHC Key Laboratory of Thrombosis and Hemostasis, National Clinical Research Center for Hematologic
2 shared publicationsBiao Yang
Jiangsu Institute of Hematology, Cyrus Tang Medical Institute, The First Affiliated Hospital Collaborative Innovation Center of Hematology, Soochow University, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, National Clinical Research Center for Hematological Diseases, Suzhou, China
1 shared publication
Latest Publications
- Open Access
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1734694
Role of albumin in regulating platelet function
Introduction: Hypoproteinemia, which occurs in diverse clinical conditions, can cause a range of complications such as thrombosis, which is among the most serious and potentially life-threatening. Albumin is a widely utilized clinical therapeutic agent; however, research regarding its regulatory effects on thrombosis remains limited, and existing clinical evidence presents conflicting findings. The precise mechanisms whereby albumin affects platelet thrombus formation require further investigation. Methods: After co-incubating albumin with platelets, various platelet function experiments were carried out. The participation of signaling pathways and protein structures in the mechanism was verified by means of Western blot technology, protein charge neutralization, and over expression of molecules. Validation was also conducted through the construction of animal models. Results: Albumin significantly inhibited platelet thrombus formation in a murine model of hypoproteinemia without inducing hemorrhagic risk. Platelet aggregation, integrin activation on the membrane surface, and ATP release induced by various agonists were all inhibited. Transmission electron microscopy and fluorescence confocal microscopy revealed that albumin could suppress granule release, alter granule distribution within platelets, and inhibit platelet spreading. Furthermore, albumin was found to reduce the phosphorylation levels of PKC and Akt in the platelet activation signaling pathway. By neutralizing the surface negative charge of albumin and adding cationic surfactants such as quaternary ammonium salts, we confirmed that the surface negative charge of albumin was critical to the inhibition of platelet aggregation and granule release. Conclusion: Albumin can inhibit platelet activation and thrombus formation through the negatively charged surface residues and by modulating the PKC and Akt signaling pathways.
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1734694
Open AccessRole of albumin in regulating platelet function
Introduction: Hypoproteinemia, which occurs in diverse clinical conditions, can cause a range of complications such as thrombosis, which is among the most serious and potentially life-threatening. Albumin is a widely utilized clinical therapeutic agent; however, research regarding its regulatory effects on thrombosis remains limited, and existing clinical evidence presents conflicting findings. The precise mechanisms whereby albumin affects platelet thrombus formation require further investigation. Methods: After co-incubating albumin with platelets, various platelet function experiments were carried out. The participation of signaling pathways and protein structures in the mechanism was verified by means of Western blot technology, protein charge neutralization, and over expression of molecules. Validation was also conducted through the construction of animal models. Results: Albumin significantly inhibited platelet thrombus formation in a murine model of hypoproteinemia without inducing hemorrhagic risk. Platelet aggregation, integrin activation on the membrane surface, and ATP release induced by various agonists were all inhibited. Transmission electron microscopy and fluorescence confocal microscopy revealed that albumin could suppress granule release, alter granule distribution within platelets, and inhibit platelet spreading. Furthermore, albumin was found to reduce the phosphorylation levels of PKC and Akt in the platelet activation signaling pathway. By neutralizing the surface negative charge of albumin and adding cationic surfactants such as quaternary ammonium salts, we confirmed that the surface negative charge of albumin was critical to the inhibition of platelet aggregation and granule release. Conclusion: Albumin can inhibit platelet activation and thrombus formation through the negatively charged surface residues and by modulating the PKC and Akt signaling pathways.
- 7 November 2024
- Published by Elsevier in Thrombosis Research
- Vol. 244, 109210
The role of protein kinase C and the glycoprotein Ibα cytoplasmic tail in anti-glycoprotein Ibα antibody-induced platelet apoptosis and thrombocytopenia
- 7 November 2024
- Published by Elsevier in Thrombosis Research
- Vol. 244, 109210
The role of protein kinase C and the glycoprotein Ibα cytoplasmic tail in anti-glycoprotein Ibα antibody-induced platelet apoptosis and thrombocytopenia
- Open Access
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11548
Platelet Glycoprotein Ibα Cytoplasmic Tail Exacerbates Thrombosis During Bacterial Sepsis
Septic patients, coupling severe disseminated intravascular coagulation (DIC) and thrombocytopenia, have poor prognoses and higher mortality. The platelet glycoprotein Ibα (GPIbα) is involved in thrombosis, hemostasis, and inflammation response. However, it remains unclear whether the GPIbα cytoplasmic tail regulates sepsis-mediated platelet activation and inflammation, especially in Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) infections. Using a mouse model of S. aureus-induced bacteremia, we found that both 10 amino acids of GPIbα C-terminal sequence deficiency and pharmacologic inhibition of protein kinase C (PKC) alleviated pathogenesis by diminishing platelet activation and aggregate formation. Furthermore, the GPIbα cytoplasmic tail promoted the phagocytosis of platelets by Kupffer cells in vivo. The genetically deficient GPIbα cytoplasmic tail also downregulated inflammatory cytokines and reduced liver damage, ultimately improving the survival rate of the septic mice. Our results illustrate that the platelet GPIbα cytoplasmic domain exacerbates excessive platelet activation and inflammation associated with sepsis through a PKC-dependent pathway. Thus, our findings provide insights for the development of effective therapeutic strategies using PKC inhibitor treatment against bacterial infection.
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11548
Open AccessPlatelet Glycoprotein Ibα Cytoplasmic Tail Exacerbates Thrombosis During Bacterial Sepsis
Septic patients, coupling severe disseminated intravascular coagulation (DIC) and thrombocytopenia, have poor prognoses and higher mortality. The platelet glycoprotein Ibα (GPIbα) is involved in thrombosis, hemostasis, and inflammation response. However, it remains unclear whether the GPIbα cytoplasmic tail regulates sepsis-mediated platelet activation and inflammation, especially in Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) infections. Using a mouse model of S. aureus-induced bacteremia, we found that both 10 amino acids of GPIbα C-terminal sequence deficiency and pharmacologic inhibition of protein kinase C (PKC) alleviated pathogenesis by diminishing platelet activation and aggregate formation. Furthermore, the GPIbα cytoplasmic tail promoted the phagocytosis of platelets by Kupffer cells in vivo. The genetically deficient GPIbα cytoplasmic tail also downregulated inflammatory cytokines and reduced liver damage, ultimately improving the survival rate of the septic mice. Our results illustrate that the platelet GPIbα cytoplasmic domain exacerbates excessive platelet activation and inflammation associated with sepsis through a PKC-dependent pathway. Thus, our findings provide insights for the development of effective therapeutic strategies using PKC inhibitor treatment against bacterial infection.